[Skip to Navigation]
September 1975

Lithium Carbonate Response in Depression: Prediction by Unipolar/Bipolar Illness, Average-Evoked Response, Catechol-O-Methyl Transferase, and Family History

Author Affiliations

From the Department of Research, Jerusalem Mental Health Center, Israel (Drs. Baron, Gershon, Rudy, and Mr. Jonas); and the Division of Clinical and Behavioral Research, National Institute of Mental Health, Bethesda, Md (Dr. Buchsbaum). Dr. Baron is now with Albert Einstein College of Medicine, New York. Dr. Gershon is now with the National Institute of Mental Health.

Arch Gen Psychiatry. 1975;32(9):1107-1111. doi:10.1001/archpsyc.1975.01760270039003

• The antidepressant efficacy of lithium carbonate was assessed in a double-blind trial in 23 hospitalized depressed patients. Unequivocal response was significantly more frequent in bipolar than in unipolar depressed patients. Lithium carbonate responders had a greater visual average-evoked response amplitude increase in response to increased stimulus intensity, termed "augmenting."

No correlation could be demonstrated between lithium carbonate efficacy and either erythrocyte catechol-O-methyl tramsferase activity, age of symptom onset, number of hospitalizations, or family history of affective disorders.

Add or change institution